Peripheral Neuropathy in Patients Receiving Pembrolizumab and Enfortumab Vedotin As First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma. an Investigator-Initiated, Prospective, Multicenter, Non-Interventional Trial.
Latest Information Update: 28 Oct 2024
At a glance
- Drugs Enfortumab vedotin (Primary) ; Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions
- Acronyms P-EVOLUTION
- 28 Oct 2024 New trial record